Spironolactone 25 mg tablets prescription in Primary Care

Background: resistant arterial hypertension is a major health problem of complex management. The new clinical practice guidelines of the European Society of Hypertension and the European Society of Cardiology recommend the use of spironolactone, an aldosterone receptor antagonist, as the fourth drug in patients with HRT. Objective: to characterize the prescription of pironolactone (25 mg) tablets in a community pharmacy in the municipality of Santa Clara. Methods: an observational, descriptive, retrospective and cross-sectional research was carried out corresponding to a study of the use of prescription-type drugs in force in the month of July 2023, of patients with a prescription of spironolactone (25 mg) tablets. Results: the over 59 years age group predominated (78.1 %), the daily dose of 2 tablets (43.1 %), consumed 3 or more drugs (51.25 %), diagnosis of Arterial Hypertension (59.4 %), concomitant with 1 (38.9 %) and 2 (35.8 %) antihypertensive drugs. Conclusions: spironolactone in 25 mg tablets is consumed mainly by elderly people, who are more susceptible to the appearance of undesirable effects.